nivolumab,brentuximab,doxorubicin hydrochloride,dacarbazine,filgrastim,pegfilgrastim,vinblastine sulfate
seagen,bms,amgen
['thanks']
thanks for a great summary of the talk - agreed it is a practice-changing study (even in countries where escbeacopp is more prevalent)
#asco23 #lymsk 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem